Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo pill may offer better blood pressure control

NCT ID NCT06236061

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jan 03, 2026 · Last updated May 14, 2026 · Updated 24 times

Summary

This study tested whether a combination of two blood pressure medicines (LCZ696 and amlodipine) works better than one medicine alone. It included 718 adults with mild to moderate hypertension that was not well controlled by LCZ696 alone. Participants received either the combo or the single drug for 8 weeks, and blood pressure changes were measured.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Novartis Investigative Site

    Nagoya, Aichi-ken, 4518511, Japan

  • Novartis Investigative Site

    Nagoya, Aichi-ken, 453-0804, Japan

  • Novartis Investigative Site

    Nagoya, Aichi-ken, 4540933, Japan

  • Novartis Investigative Site

    Nagoya, Aichi-ken, 4578511, Japan

  • Novartis Investigative Site

    Itoshima, Fukuoka, 8191104, Japan

  • Novartis Investigative Site

    Chitose, Hokkaido, 066-0032, Japan

  • Novartis Investigative Site

    Sapporo, Hokkaido, 30026, Japan

  • Novartis Investigative Site

    Sapporo, Hokkaido, 630826, Japan

  • Novartis Investigative Site

    Sapporo, Hokkaido, 630842, Japan

  • Novartis Investigative Site

    Akashi, Hyōgo, 674-0081, Japan

  • Novartis Investigative Site

    Amagasaki, Hyōgo, 660-0861, Japan

  • Novartis Investigative Site

    Tsukuba, Ibaraki, 3050861, Japan

  • Novartis Investigative Site

    Kamakura, Kanagawa, 247-0055, Japan

  • Novartis Investigative Site

    Kawasaki-shi, Kanagawa, 211-0041, Japan

  • Novartis Investigative Site

    Yokohama, Kanagawa, 231-0023, Japan

  • Novartis Investigative Site

    Yokohama, Kanagawa, 232-0064, Japan

  • Novartis Investigative Site

    Ōsaki, Miyagi, 989-6143, Japan

  • Novartis Investigative Site

    Sendai, Miyagi, 980-0011, Japan

  • Novartis Investigative Site

    Sendai, Miyagi, 9830039, Japan

  • Novartis Investigative Site

    Suita, Osaka, 5650853, Japan

  • Novartis Investigative Site

    Chiyoda City, Tokyo, 101-0041, Japan

  • Novartis Investigative Site

    Chuo Ku, Tokyo, 104-0031, Japan

  • Novartis Investigative Site

    Chuo-ku, Tokyo, 1030027, Japan

  • Novartis Investigative Site

    Hachiōji, Tokyo, 192-0046, Japan

  • Novartis Investigative Site

    Kiyose, Tokyo, 204-0021, Japan

  • Novartis Investigative Site

    Musashino, Tokyo, 1800022, Japan

  • Novartis Investigative Site

    Nerima Ku, Tokyo, 1770051, Japan

  • Novartis Investigative Site

    Setagaya-ku, Tokyo, 1550031, Japan

  • Novartis Investigative Site

    Shibuya City, Tokyo, 150-0013, Japan

  • Novartis Investigative Site

    Shinagawa-Ku, Tokyo, 141-0032, Japan

  • Novartis Investigative Site

    Shinjuku Ku, Tokyo, 160-0008, Japan

  • Novartis Investigative Site

    Shinjuku-ku, Tokyo, 1600017, Japan

  • Novartis Investigative Site

    Shinjuku-ku, Tokyo, 1690072, Japan

  • Novartis Investigative Site

    Suginami-ku, Tokyo, 166-0003, Japan

  • Novartis Investigative Site

    Toshima-Ku, Tokyo, 171-0021, Japan

  • Novartis Investigative Site

    Chuoh-ku, 104-0031, Japan

  • Novartis Investigative Site

    Fukuoka, 810-0021, Japan

  • Novartis Investigative Site

    Hiroshima, 732-0053, Japan

  • Novartis Investigative Site

    Kyoto, 615-8125, Japan

  • Novartis Investigative Site

    Osaka, 5300002, Japan

  • Novartis Investigative Site

    Osaka, 5320003, Japan

  • Novartis Investigative Site

    Osaka, 536-0008, Japan

  • Novartis Investigative Site

    Osaka, 550-0013, Japan

Conditions

Explore the condition pages connected to this study.

HYPERTENSION